"exploratory endpoints" is correct and usable in written English.
You can use it to refer to the outcomes of a study that are used to learn more about the initial findings observed. For example, "The research team identified several exploratory endpoints that could provide insight into the potential impact of the intervention."
The exploratory endpoints will assess potential biomarkers of treatment response.
Other exploratory endpoints will examine the phenotype of neutrophils and monocyte/macrophages in sputum.
Other efficacy parameters, including changes from baseline in FVC, DLCO, and HRCT/fibrosis score, were exploratory endpoints.
This includes, for example, details about proprietary information about analytical methods, or so-called exploratory endpoints that could provide clues of potential off-label uses to competitors.
Exploratory endpoints including the Hammersmith Motor Function Scale - Expanded (HFMSE) in all subjects, and electrophysiological measures in cohort 4 only, were performed to gain further experience with these measures.
Changes from baseline in mean monthly EA-ID and PI-ID over the final 3 months (months 4 6) of the double-blind treatment phase (DBTP) were assessed as pre-specified exploratory endpoints in the STRIVE trial; primary and secondary endpoints are reported separately.
The use of EXACT for exacerbations and E-RS for respiratory symptoms in patients with COPD is further supported by FDA and European Medicines Agency Guidance, which qualify these PRO measures for use as exploratory endpoints in clinical trials [27, 28].
Primary and secondary endpoints were assessed at Week 12. Exploratory endpoints included: change from baseline in migraine-specific quality of life (QoL) measured by the Migraine-Specific QoL Questionnaire (MSQ), headache impact measured by the Headache Impact Test (HIT-6), and migraine-related disability measured by the Migraine Disability Assessment Test (MIDAS).
Exploratory endpoints included: changes in blood biomarkers KL-6, MMP-1, MMP-7, SP-A and SP-D, TIMP-1, CCL-18, CCL-2, PAI-1, and tenascin C; changes in FVC and DLCO from baseline; and change in HRCT pulmonary fibrosis score from baseline.
The immunological analyses presented here were exploratory endpoints.
